David E Gyorki
Overview
Explore the profile of David E Gyorki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
2249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mor E, Mor-Hadar D, Henderson M, Snow H, Gyorki D
ANZ J Surg
. 2025 Mar;
PMID: 40071744
Purpose: Retroperitoneal sarcomas (RPS) present a surgical challenge due to their complex anatomical relationships to organs and vascular structures. In this limited case series, we reconstructed the tumour beds of...
2.
Ormston T, Duarte J, Quigley L, Jackett L, Whitlam J, Behren A, et al.
Front Immunol
. 2024 Nov;
15:1474663.
PMID: 39544941
Introduction: We report the partial regression of metastatic squamous cell carcinoma (SCC) after reduction of long-term azathioprine therapy while awaiting surgery. The patient was a 69-year-old man with a history...
3.
DePalo D, Dugan M, Naqvi S, Ollila D, Hieken T, Block M, et al.
Cancer
. 2024 Nov;
131(1):e35636.
PMID: 39522025
Background: Isolated limb infusion and perfusion (ILI/ILP) has been a mainstay treatment for unresectable melanoma in-transit metastases (ITM), but increased use of immune checkpoint inhibitors (ICI) and intralesional therapy (talimogene...
4.
Gyorki D, Bae S, Carey Smith R, Caruso D, Coker D, Connolly E, et al.
ANZ J Surg
. 2024 Oct;
PMID: 39475177
No abstract available.
5.
Mor E, Baker B, Henderson M, Lazarakis S, Mitchell C, Speakman D, et al.
ANZ J Surg
. 2024 Sep;
94(12):2150-2158.
PMID: 39253994
Purpose: Radiation-induced angiosarcoma (RIAS) of the breast is a rare tumour with high rate of local recurrence. The aim of this study is to evaluate the outcome of radical resections....
6.
Mor E, Snow H, Gyorki D
Ann Surg Oncol
. 2024 Jul;
31(10):7208-7209.
PMID: 38954097
No abstract available.
7.
Long G, Carlino M, Au-Yeung G, Spillane A, Shannon K, Gyorki D, et al.
Nat Med
. 2024 Jun;
30(9):2540-2548.
PMID: 38907159
Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma. Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically. In the non-comparative,...
8.
Mor E, Tejman-Yarden S, Mor-Hadar D, Assaf D, Eifer M, Nagar N, et al.
Ann Surg Oncol
. 2024 Jun;
31(10):7198-7205.
PMID: 38898325
Background: Retroperitoneal sarcomas (RPSs) present a surgical challenge, with complex anatomic relationships to organs and vascular structures. This pilot study investigated the role of three-dimensional (3D) augmented reality (3DAR) compared...
9.
Blank C, Lucas M, Scolyer R, van de Wiel B, Menzies A, Lopez-Yurda M, et al.
N Engl J Med
. 2024 Jun;
391(18):1696-1708.
PMID: 38828984
Background: In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. Methods: In this phase 3 trial, we randomly assigned...
10.
Webster S, Vargas A, Maclean F, Vu J, Tong E, Coker D, et al.
Crit Rev Oncol Hematol
. 2024 Apr;
197:104354.
PMID: 38614268
Preoperative biopsy for retroperitoneal sarcoma (RPS) enables appropriate multidisciplinary treatment planning. A systematic review of literature from 1990 to June 2022 was conducted using the population, intervention, comparison and outcome...